TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Trump Buys SpaceX Shares After Record IPO 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Add as a preferred source on Google
GAITHERSBURG, Md., May 02, 2018 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, May 9, 2018.
Conference call details are as follows:
| Date: | May 9, 2018 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, May 9, 2018 until | |
| 7:30 p.m. ET May 16, 2018 | ||
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until August 9, 2017 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Its RSV and influenza nanoparticle vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of Novavax’ efforts to improve global health. For more information, please visit www.novavax.com.
Contact:
Investors
Erika Trahan
Senior Manager, Investor & Public Relations
[email protected]
240-268-2000
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Sam Brown
Mike Beyer
[email protected]
312-961-2502
